๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Multiple Myeloma, Refractory
Clinical trial register · United States · industry-sponsored

Multiple Myeloma, Refractory Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
Florida 3 California 3 Arkansas 1 Iowa 1 New York 1
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to
7 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma
NCT07802717Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Vyriad, Inc.
Phase 1
40
Minnesota
2026-09-08
Recruiting
Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma
NCT07772024Multiple Myeloma Refractory, Multiple Myeloma in Relapse
CellCentric Ltd.
Phase 3
450
Florida
2026-08
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
CellCentric Ltd.
Phase 2
100
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-01-22
Recruiting
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
NCT06225310Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Oncotherapeutics
Phase 1
30
California
2024-08-06
Recruiting
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT06115135Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Oncotherapeutics
Phase 2
39
California, Nebraska
2024-06-20
Recruiting
LMY-920 for Treatment of Relapsed or Refractory Myeloma
NCT05546723Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
Luminary Therapeutics
Phase 1
30
Ohio
2024-03-13
Active, closed
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
NCT05673083Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
All4Cure
Observational
200
Arkansas, Florida, Iowa, New York, Oklahoma, Texas, Washington
2023-03-01
Rows per page Showing 1–7 of 7
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/multiple-myeloma-refractory

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.